DDInter302 DDInter1435
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Carmustine {u} (Compound) treats {v} (Disease) melanoma
Carmustine {u} (Compound) binds {v} (Gene) CYP1A2
Carmustine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Carmustine {u} (Compound) causes {v} (Side Effect) Vision blurred
Carmustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Carmustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Carmustine {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Carmustine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Carmustine (Compound) treats melanoma (Disease)
Carmustine (Compound) binds CYP1A2 (Gene)
Carmustine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Carmustine (Compound) causes Vision blurred (Side Effect)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Carmustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Carmustine may lead to a major life threatening interaction when taken with Cladribine